Novo Nordisk Annual Report 2021
Contents Introducing Novo Nordisk
Strategic Aspirations Key risks Management
Consolidated statements
Additional information
Novo Nordisk Annual Report 2021
53
Equity statement
at 31 December
DKK million
Balance at the beginning of the year
Net profit
Other comprehensive income
Total comprehensive income
Transfer of cash flow hedge reserve to
intangible assets (note 4.2)
Transactions with owners:
Dividends (note 4.1)
Share-based payments (note 5.1)
Tax related to restricted stock units
Purchase of treasury shares (note 4.2)
Reduction of the B share capital (note 4.2)
Balance at the end of the year
Refer to note 4.2 for details of movements in Other reserves.
2021
2020
2019
Share Treasury
capital
Retained
Other
shares
470
(8)
earnings reserves
63,774
47,757
Total
Share
capital
Treasury
shares
(911)
63,325
480
47,757
Retained
earnings reserves
(10) 57,817
42,138
Other
Total
Share
capital
Treasury
shares
Retained
earnings reserves
Other
Total
(694)
57,593
490
(11)
42,138
53,406
38,951
(2,046)
51,839
38,951
146
(816)
(670)
(67)
(543)
(610)
(187)
1,352
1,165
47,903
(816)
47,087
42,071
(543)
41,528
38,764
1,352
40,116
13
13
326
326
(21,517)
(21,517)
1,040
1,040
(20,121)
823
(20,121)
823
(19,409)
363
(19,409)
363
245
245
31
31
18
18
(6)
(19,441)
(19,447)
(8)
(16,847)
(16,855)
(9) (15,325)
(15,334)
(8)
8
(10)
10
(10)
10
462
(6)
72,004 (1,714)
70,746
470
(8)
63,774
(911)
63,325
480
(10)
57,817
(694)
57,593View entire presentation